Ironwood Pharmaceuticals (IRWD) to Release Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Ironwood Pharmaceuticals to post earnings of $0.02 per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:30 AM ET.

Ironwood Pharmaceuticals Stock Performance

IRWD opened at $4.78 on Thursday. The company has a market capitalization of $777.61 million, a PE ratio of 29.88 and a beta of 0.17. The stock’s fifty day moving average is $4.23 and its 200-day moving average is $2.69. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.78.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Zacks Research upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 1st. Wells Fargo & Company lifted their target price on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a report on Monday, January 5th. Citizens Jmp raised Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price for the company in a report on Monday, January 5th. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $3.68.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC acquired a new position in Ironwood Pharmaceuticals in the 4th quarter worth about $34,000. Cibc World Markets Corp acquired a new position in Ironwood Pharmaceuticals in the fourth quarter worth approximately $36,000. Evolve Private Wealth LLC bought a new position in Ironwood Pharmaceuticals during the fourth quarter valued at approximately $50,000. Abel Hall LLC acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at approximately $56,000. Finally, Integrated Wealth Concepts LLC grew its position in Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,406 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.